南方医科大学学报

南方医科大学学报 ›› 2013, Vol. 33 ›› Issue (09): 1336-.

• • 上一篇    下一篇

膀胱尿路上皮癌中CD133、CD82/KAI1的表达及其与血管生成拟态的关系

俞岚，武世伍，周蕾，宋文庆，王丹娜   

  • 出版日期:2013-09-20 发布日期:2013-09-20

Expressions of CD133 and CD82/KAI1 in bladder urothelial carcinoma and their correlation with vasculogenic mimicry

  • Online:2013-09-20 Published:2013-09-20

PDF

1303

摘要： 目的研究膀胱尿路上皮癌中CD133、CD82/KAI1蛋白与膀胱尿路上皮癌患者各临床病理因素之间的关系。方法采用
免疫组织化学ElivisionTM plus法和特殊组织化学法检测90例膀胱尿路上皮癌和20例正常膀胱粘膜中CD133、CD82/KAI1的表
达和血管生成拟态（VM）的形成情况。结果在正常膀胱粘膜组织中CD133、CD82/KAI1蛋白的表达阳性率和VM检出率分别
为0%、90.0%和0%，在尿路上皮癌组织中三者表达分别为65.6%、31. 1%和31.1%，差异均有显著性（P<0.01）。膀胱尿路上皮癌
中，CD133、CD82/KAI1蛋白阳性表达以及VM的形成与患者的性别、年龄、肿瘤的数量均无相关性（P>0.05）；而与肿瘤分化程
度、临床病理分期以及复发与否具有相关性（P<0.01）。癌组织中，CD82/KAI1的表达与VM的形成及CD133的表达成负相关
性（r=-0.452，-0.776，P<0.01-0.05），CD133的表达与VM的形成呈正相关（r=0.487，P<0.05）。结论CD133、CD82/KAI1参与膀
胱尿路上皮癌中VM形成，并且CD133、CD82/KAI1以及VM共同参与尿路上皮癌的侵袭及复发。

Abstract: Objective To explore the expressions of CD133 and CD82/KAI1 in bladder urothelial carcinoma, their association
with the clinicopathological factors and their roles in vasculogenic mimicry (VM) in the tumor. Methods The expressions of
CD133 and CD82/KAI1 and VM were detected by immunohistochemistry and histochemistry in 90 specimens of bladder
urothelial carcinoma and 20 specimens of normal bladder epithelium tissue. Results The positivity rates of CD133, CD82/KAI1
and VM in normal bladder epithelium tissue were 0, 90% and 0, showing significant differences from the rates of 65.6%, 31.1%
and 31.1% in urothelial carcinoma, respectively (P<0.01). Positive expressions of CD133, CD82/KAI1 and VM were significantly
correlated with pTNM stage and tumor relapse (P<0.01) but not with gender, age, or tumor numbers (P>0.05). CD133
expression was positively correlated with VM (P=0.487, P<0.05), and CD82/KAI1 expression was negatively correlated with
VM (r=-0.452, P<0.01) and CD133 (r=-0.776, P<0.05). Conclusion The expressions of CD133 and CD82/KAI1 proteins are
involved in the occurrence of VM in bladder urothelial carcinoma to contribute to the invasion and relapse of bladder
carcinoma.